LA PRIMA NOTIZIA
https://www.bmj.com/content/374/bmj.n2098
Covid-19: 40% of patients with weakened immune system …
The BMJ. Four in 10 people who are clinically vulnerable generate lower levels of antibodies than healthy recipients after two shots of vaccine against SARS-CoV-2, a study has found.
The Octave (Observational Cohort Trial T cells Antibodies and Vaccine Efficacy in SARS-CoV-2) trial is one of the largest in the world to have looked at the response to covid-19 vaccination in patients who are immunocompromised. It compared 600 patients, who had a weakened immune system because of their disease process or treatment, with the antibody response of healthy people from the Pitch (Protective Immunity from T Cells in Healthcare workers) study.
The trial included patients with solid organ and haematological cancers, end stage kidney and liver disease, organ transplants, and immune mediated inflammatory disease such as inflammatory bowel disease, vasculitis, or rheumatoid arthritis—patients who were not included in original vaccine trial data.
The findings, published as a preprint on the Lancet site,1 showed that 89% of immunocompromised patients seroconverted within four weeks of the second vaccine dose, as compared with 100% of healthy participants in the Pitch trial.
Overall, 60% of immunocompromised patients had an antibody response equivalent to that of healthy vaccine recipients, but 11% of those with a weakened immune system failed to generate any antibodies.
Failure to seroconvert was particularly high in certain groups: 72.4% of patients with ANCA associated vasculitis and 98% of patients with inflammatory arthritis were in this category. Notably, all of the patients with ANCA associated vasculitis had received rituximab, a targeted B cell depletion therapy, and the researchers suspect a possible link between low seroconversion and rituximab because of the importance of B cells in the immune response to covid-19.
LA SECONDA NOTIZIA
“Vaccino efficace tra il 19% e il 29%” Lo studio clamoroso …
Mentre hanno già sfondato la barriera del milione i vaccini contro il covid somministrati in Italia, emergono novità sulla sicurezza del prodotto che se confermate potrebbero preoccupare non poco. Stando a un articolo pubblicato di recente sul British Medical Journal e firmato da Peter Doshi, professore di ricerca sui servizi sanitari farmaceutici …
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4037 (Published 21 October 2020)Cite this as: BMJ 2020;371:m4037